Related Experiment Video
Updated: Jun 14, 2026
08:47
Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
Pathogenic mechanisms and experimental models of multiple sclerosis
Anthony Slavin1, Louise Kelly-Modis, Mark Labadia
1Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06887, USA. anthony.slavin@boehringer-ingelheim.com
Autoimmunity
|April 13, 2010
Summary
Multiple sclerosis (MS) treatments like interferons and glatiramer acetate have limited effectiveness. New therapies targeting multiple cell types show promise but require careful risk assessment and better biomarkers for efficacy monitoring.
Area of Science:
- Neuroimmunology
- Autoimmune Diseases
Background:
- Multiple sclerosis (MS) is a significant autoimmune disorder impacting over a million individuals globally, causing demyelination and axonal loss.
- Current first-line therapies, including type I interferons (IFN-I) and glatiramer acetate (GA), exhibit limited efficacy, necessitating novel therapeutic approaches.
Purpose of the Study:
- This review synthesizes current knowledge on MS therapies, clinical trial outcomes, genetic factors, cellular players, animal models, gene expression, and biomarkers.
- To highlight the need for improved therapeutic strategies and monitoring tools in MS management.
Main Methods:
- Review of existing literature on multiple sclerosis pathogenesis and treatment.
- Analysis of clinical trial data, including successes and failures of therapeutic targets.
- Examination of animal models, specifically experimental autoimmune encephalomyelitis (EAE), for their predictive value in MS therapy.
Main Results:
- Tysabri, an anti-very late antigen-4 antibody, demonstrates greater efficacy by blocking multiple cell types, unlike IFNs or GA.
- While Tysabri shows increased efficacy, it carries a risk of progressive multifocal leukoencephalopathy.
- Therapeutic strategies effective in EAE models, such as TNFα antagonists, have failed in clinical settings, indicating limitations in translational value.
Conclusions:
- Blocking transmigration of multiple pathogenic cell types, including T cells and B cells, may enhance MS therapy effectiveness.
- The predictive value of the EAE animal model for MS treatment efficacy is limited.
- Development of clinical biomarkers is crucial for monitoring treatment efficacy and advancing MS management.
